# Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

> **NCT04658472** · PHASE2 · COMPLETED · sponsor: **Bioverativ, a Sanofi company** · enrollment: 98 (actual)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy

## Interventions

- **DRUG:** SAR445088 (IV)
- **DRUG:** SAR445088 (SC)

## Key facts

- **NCT ID:** NCT04658472
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-28
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04658472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04658472, "Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04658472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*